159. 色素性乾皮症 Xeroderma pigmentosum Clinical trials / Disease details


臨床試験数 : 11 薬物数 : 17 - (DrugBank : 5) / 標的遺伝子数 : 5 - 標的パスウェイ数 : 15

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2021-001419-10-ES
(EUCTR)
31/01/202217/11/2021Study to evaluate the safety and the efficacy of the photoprotective drug, afamelanotide in patients with Xeroderma Pigmentosum C and VA Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - Phase IIa XPC and XPV Study Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: Afamelanotide (16 mg implant)
CLINUVEL EUROPE LIMITEDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Belgium;Spain
2EUCTR2021-003642-20-DE
(EUCTR)
27/09/202109/07/2021Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP)A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous Implants of Afamelanotide in Patients withXeroderma Pigmentosum (XP) - Phase IIa XP Study xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: SCENESSE
INN or Proposed INN: Afamelanotide
CLINUVEL EUROPE LTDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Germany
3EUCTR2019-000597-34-DE
(EUCTR)
01/06/202111/01/2021Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients withXeroderma Pigmentosum (XP)A Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety andEfficacy of Subcutaneous Implants of Afamelanotide in Patients withXeroderma Pigmentosum (XP) - Phase IIa XP Study xeroderma pigmentosum;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: SCENESSE
INN or Proposed INN: AFAMELANOTIDE
CLINUVEL EUROPE LIMITEDNULLNot RecruitingFemale: yes
Male: yes
6Phase 2Germany
4EUCTR2021-001419-10-BE
(EUCTR)
16/11/2021Study to evaluate the safety and efficacy of the photoprotective drug, afamelanotide in patients with Xeroderma Pigmentosum C and VA Proof of Concept, Phase IIa, Open Label Study to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide in Patients with Xeroderma Pigmentosum C and V (XPC and XPV) - Phase IIa XPC and XPV Study Patients with Xeroderma Pigmentosum C and V;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SCENESSE
Product Name: Afamelanotide (16 mg implant)
CLINUVEL EUROPE LIMITEDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
6Phase 2Spain;Belgium